On April 2, 2026, CanWell Pharma announced that the research progress of three of its self-developed pipelines has been selected for the poster presentation session at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
The AACR Annual Meeting is one of the most influential academic events in the global cancer research field, and this year’s meeting is scheduled to be held from April 17 to 22, 2026 at the San Diego Convention Center in California, USA.
Date: April 17 – 22, 2026
Address: San Diego Convention Center
- CAN016, a HER2-targeted dual-payload ADC, phase 1 clinical development
Session Title：
Phase I and Phase II Clinical Trials in Progress
Session Start Time: 4/21/2026 2:00:00 PM
Session End Time: 4/21/2026 5:00:00 PM
Location: Poster Section 51
Poster Board Number: 26
Presentation Number: CT292
- A novel StarLinker-based, CLDN18.2/PD-L1 bispecific dual-payload ADC (CAN017) overcomes tumor heterogeneity
Session Title：
Overcoming Microenvironmental and Delivery Barriers in Cancer Therapy
Session Start Time: 4/22/2026 9:00:00 AM
Session End Time: 4/22/2026 12:00:00 PM
Location: Poster Section 15
Poster Board Number: 18
Presentation Number: 7161
- A phase 1 study of CAN2109, a novel,long-acting, tumor-retained, immunoegenic cell death inducer
Session Title：
Phase I Clinical Trials in Progress
Session Start Time: 4/20/2026 9:00:00 AM
Session End Time: 4/20/2026 12:00:00 PM
Location: Poster Section 51
Poster Board Number: 5
Presentation Number: CT074